Pharsight

News

Feb 21, 2024
Polpharma Biologics has announced topline results showing the pharmacokinetic (PK) and pharmacodynamics (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio (vedolizumab). The results confirm the potential of PB016 as a more affordable option for the 3.5 million patients suffering from inflammatory bowel diseases. The company is currently conducting a global clinical safety & efficacy study in patients with ulcerative colitis to provide further evidence of PB016's efficacy, safety, and immunogenicity.
Feb 21, 2024
Polpharma Biologics announces positive topline results from a study demonstrating the pharmacokinetic and pharmacodynamics comparability of its biosimilar candidate, PB016, to the reference drug Entyvio. The results confirm PB016 as a potential more affordable option for the treatment of inflammatory bowel diseases. Polpharma Biologics is currently conducting further studies to provide evidence on the efficacy, safety, and immunogenicity of PB016 compared to the reference drug.
Feb 21, 2024
GSK's long-acting HIV drug, Cabenuva, has shown promising results in a trial, outperforming daily pills for patients who struggle with adherence. ViiV Healthcare, a unit of GSK, announced that all participants in the study will now be offered the injectable drug. Cabenuva, administered as two shots every four weeks, was approved in the US last year.
Feb 21, 2024
U.S.-based Eli Lilly and Denmark's Novo Nordisk are experiencing a surge in their shares due to the success of their weight-loss drugs, GLP-1 agonists. Analysts expect the market for obesity drugs to exceed $100 billion. Eli Lilly's market value recently surpassed electric automaker Tesla, making it the ninth-largest U.S.-listed company. Wall Street analysts predict significant growth for both companies in the coming years. However, the rally could be at risk if sales disappoint or if there are substantial increases in production costs or price reductions.
Read more about | NOVO NORDISK INC | ELI LILLY AND CO |
Feb 21, 2024
The FDA has accepted the BLA submission for the drug datopotamab deruxtecan, developed by Daiichi Sankyo and AstraZeneca, in non-squamous non-small cell lung cancer (NSCLC) patients. The drug, an antibody-drug conjugate (ADC), showed promising results in a Phase III study, with improved progression-free survival and overall response rates compared to standard chemotherapy. GlobalData estimates that the drug could earn $3.12 billion by 2029. The companies also have other ADCs in their pipeline, including the successful Enhertu (trastuzumab deruxtecan).
Read more about | DAIICHI SANKYO INC | ASTRAZENECA AB |
Feb 20, 2024
Indian pharmaceutical companies Cipla, Sun Pharma, and Dr. Reddy's have seen strong earnings due to sales of the blockbuster cancer drug Revlimid. However, their growth may be affected in the coming quarters due to the expected entry of competitors and the expiration of the drug's patent in 2026. The companies will need to find new sources of revenue to sustain earnings growth. Dr. Reddy's is looking at acquisitions and faster product filings, while Cipla is banking on the launch of respiratory drug Advair and cancer drug Abraxane. Sun Pharma is focusing on global specialty products to reduce dependence on US generics.
Read more about | REVLIMID| ABRAXANE|
Feb 20, 2024
The global active pharmaceutical ingredient (API) market is predicted to reach $307.5 billion by 2034, growing at a CAGR of 4%. The market is driven by factors such as the increasing demand for generic drugs, outsourcing trends, the rise of biologics, and regulatory compliance requirements. Key players in the market include Bristol-Myers Squibb, Pfizer, and Boehringer Ingelheim. The market's competitive landscape includes established pharmaceutical companies, contract manufacturing organizations (CMOs), and emerging entities.
Feb 20, 2024
Richard Gonzalez, the founding CEO of AbbVie Inc., will step down on July 1 and will be replaced by the current president and COO, Robert Michael. Gonzalez will become the executive chair of the board of directors. The leadership change comes as AbbVie deals with competition for its autoimmune drug Humira and closes acquisitions. Gonzalez praised Michael for his role in navigating the transition of Humira. AbbVie has been planning for the CEO succession for some time and has ensured the right plan is in place for a potential successor.
Read more about | ABBVIE INC |
Feb 19, 2024
The US Food and Drug Administration (FDA) has accepted for review Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Dato-DXd) for the treatment of non-small cell lung cancer. The drug is a TROP2-directed antibody-drug conjugate and has shown positive results in a Phase III trial. AstraZeneca's Tagrisso and Enhertu are also expected to gain more approvals in the cancer market, and the non-small cell lung cancer market is predicted to reach over $45.4bn by 2031.
Feb 19, 2024
AstraZeneca's shares rose after trial data showed that its drug, Tagrisso, slowed disease progression in patients with advanced lung cancer. The trial focused on Tagrisso as a maintenance therapy for patients with non-small cell lung cancer and a specific genetic mutation. AstraZeneca stated that the trial demonstrated a significant improvement in progression-free survival for patients who had received initial chemoradiation. Tagrisso was recently approved by the US FDA for advanced non-small cell lung cancer. The drug is currently AstraZeneca's top oncology earner.
Read more about | ASTRAZENECA AB | TAGRISSO|